Key result
Chronic treatment with prednisolone caused significant muscle wasting and completely abrogated the muscle hypertrophic effects of myostatin inhibition in dystrophic mice.
Why the study?
The study was conducted to investigate how chronic glucocorticoid treatment impacts the efficacy of myostatin inhibition in the D2.mdx mouse model of Duchenne muscular dystrophy.
Does chronic prednisolone treatment counteract the hypertrophic effects of myostatin inhibition in mdx mouse models of Duchenne muscular dystrophy?
Population
D2.mdx mouse model of DMD
Comparison
Prednisolone combined with myostatin inhibition vs alone or control
Design
Preclinical animal study
Authors
Loading...
Glucocorticoids may blunt myostatin inhibition benefits in DMD models; leaves open whether combination strategies merit clinical testing.
Does chronic prednisolone treatment counteract the hypertrophic effects of myostatin inhibition in mdx mouse models of Duchenne muscular dystrophy?
Chronic glucocorticoid treatment induces muscle atrophy and completely abrogates the muscle hypertrophic effects of myostatin inhibition in dystrophic mice, highlighting a critical drug interaction for DMD clinical trials.
Hammers et al. (2019) studied Duchenne muscular dystrophy. Prednisolone and AAV8.dnMstn (myostatin inhibitor) vs. Vehicle and/or PBS was evaluated on Skeletal muscle mass and body weight. Chronic treatment with prednisolone caused significant muscle wasting and completely abrogated the muscle hypertrophic effects of myostatin inhibition in dystrophic mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: